MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 127848 | Name: Etripamil HCl

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Etripamil is a calcium channel blocker. Calcium channel blockers (CCB), calcium channel antagonists or calcium antagonists are several medications that disrupt the movement of calcium (Ca2+) through calcium channels. Calcium channel blockers are used as antihypertensive drugs, i.e., as medications to decrease blood pressure in patients with hypertension.

Chemical Structure

Etripamil HCl
Etripamil HCl
CAS#2560549-35-9 (HCl)

Theoretical Analysis

MedKoo Cat#: 127848

Name: Etripamil HCl

CAS#: 2560549-35-9 (HCl)

Chemical Formula: C27H37ClN2O4

Exact Mass: 488.2442

Molecular Weight: 489.05

Elemental Analysis: C, 66.31; H, 7.63; Cl, 7.25; N, 5.73; O, 13.09

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
2560549-35-9 (HCl) 1593673-23-4 (free base)
Synonym
Etripamil hydrochloride; Etripamil HCl; (-)-MSP-2017 HCl; MSP-2017; MSP 2017; MSP2017; MSP-2017A; MSP-2017B;
IUPAC/Chemical Name
methyl (S)-3-(2-((4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl)(methyl)amino)ethyl)benzoate hydrochloride
InChi Key
JHOAIMAMBNLIMD-YCBFMBTMSA-N
InChi Code
InChI=1S/C27H36N2O4.ClH/c1-20(2)27(19-28,23-11-12-24(31-4)25(18-23)32-5)14-8-15-29(3)16-13-21-9-7-10-22(17-21)26(30)33-6;/h7,9-12,17-18,20H,8,13-16H2,1-6H3;1H/t27-;/m0./s1
SMILES Code
Cl.COC(=O)C1=CC=CC(CCN(C)CCC[C@](C#N)(C(C)C)C2=CC(OC)=C(OC)C=C2)=C1
Appearance
To be determined
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 -4 C for short term (days to weeks) or -20 C for long term(months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 489.05 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Huston J, Genovese A, Ashchi A, DeLuca A, Wiener J, Deeb E, Deeb A, Goldfaden RF. Etripamil Nasal Spray: Therapeutic Potential for Treating Paroxysmal Supraventricular Tachycardia. Am J Cardiovasc Drugs. 2023 Sep;23(5):471-475. doi: 10.1007/s40256-023-00589-2. Epub 2023 Jun 6. Erratum in: Am J Cardiovasc Drugs. 2023 Jul 21;: PMID: 37278974. 2: Raja JM, Cave B, Jefferies JL, Khouzam RN. Etripamil: Intranasal Calcium Channel Blocker: A Novel Noninvasive Modality in the Treatment of Paroxysmal Supraventricular Tachycardia. Curr Probl Cardiol. 2021 Mar;46(3):100430. doi: 10.1016/j.cpcardiol.2019.05.003. Epub 2019 Jun 22. PMID: 31279494. 3: Kashou AH, Noseworthy PA. Etripamil nasal spray: an investigational agent for the rapid termination of paroxysmal supraventricular tachycardia (SVT). Expert Opin Investig Drugs. 2020 Jan;29(1):1-4. doi: 10.1080/13543784.2020.1703180. Epub 2019 Dec 12. PMID: 31825681. 4: Chu GS, Gupta D. Update on Etripamil Nasal Spray for the At-home Treatment of Acute Paroxysmal Supraventricular Tachycardia. Heart Int. 2021 Jul 15;15(1):2-6. doi: 10.17925/HI.2021.15.1.2. PMID: 36277324; PMCID: PMC9524608. 5: Faisaluddin M, Ashish K, Hajra A, Mondal S, Bandyopadhyay D. Etripamil: Self- management of supraventricular tachycardia is not far away? Int J Cardiol Heart Vasc. 2019 Jan 4;22:82-83. doi: 10.1016/j.ijcha.2018.12.007. PMID: 30627628; PMCID: PMC6321861. 6: Weintraub S, Frishman WH. A Novel Calcium Channel Blocker: Etripamil: What is the Future of Intranasal Drug Delivery in the Treatment of Cardiac Arrhythmias? Cardiol Rev. 2021 Sep-Oct 01;29(5):253-258. doi: 10.1097/CRD.0000000000000362. PMID: 33060411. 7: Ip JE, Coutu B, Bennett MT, Pandey AS, Stambler BS, Sager P, Chen M, Shardonofsky S, Plat F, Camm AJ. Etripamil Nasal Spray for Conversion of Repeated Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia During Long-Term Follow-Up: Results From the NODE-302 Study. J Am Heart Assoc. 2023 Oct 3;12(19):e028227. doi: 10.1161/JAHA.122.028227. Epub 2023 Sep 27. PMID: 37753718. 8: Stambler BS, Dorian P, Sager PT, Wight D, Douville P, Potvin D, Shamszad P, Haberman RJ, Kuk RS, Lakkireddy DR, Teixeira JM, Bilchick KC, Damle RS, Bernstein RC, Lam WW, O'Neill G, Noseworthy PA, Venkatachalam KL, Coutu B, Mondésert B, Plat F. Etripamil Nasal Spray for Rapid Conversion of Supraventricular Tachycardia to Sinus Rhythm. J Am Coll Cardiol. 2018 Jul 31;72(5):489-497. doi: 10.1016/j.jacc.2018.04.082. PMID: 30049309. 9: Huston J, Genovese A, Ashchi A, DeLuca A, Wiener J, Deeb E, Deeb A, Goldfaden RF. Correction to: Etripamil Nasal Spray: Therapeutic Potential for Treating Paroxysmal Supraventricular Tachycardia. Am J Cardiovasc Drugs. 2023 Nov;23(6):735-736. doi: 10.1007/s40256-023-00595-4. Erratum for: Am J Cardiovasc Drugs. 2023 Sep;23(5):471-475. PMID: 37477826. 10: Stambler BS, Camm AJ, Alings M, Dorian P, Heidbuchel H, Houtgraaf J, Kowey PR, Merino JL, Mondésert B, Piccini JP, Pokorney SD, Sager PT, Verma A, Wharton JM, Bharucha DB, Plat F, Shardonofsky S, Chen M, Ip JE; RAPID Investigators. Self-administered intranasal etripamil using a symptom-prompted, repeat-dose regimen for atrioventricular-nodal-dependent supraventricular tachycardia (RAPID): a multicentre, randomised trial. Lancet. 2023 Jul 8;402(10396):118-128. doi: 10.1016/S0140-6736(23)00776-6. Epub 2023 Jun 15. PMID: 37331368. 11: Stambler BS, Plat F, Sager PT, Shardonofsky S, Wight D, Potvin D, Pandey AS, Ip JE, Coutu B, Mondésert B, Sterns LD, Bennett M, Anderson JL, Damle R, Haberman R, Camm AJ. First Randomized, Multicenter, Placebo-Controlled Study of Self-Administered Intranasal Etripamil for Acute Conversion of Spontaneous Paroxysmal Supraventricular Tachycardia (NODE-301). Circ Arrhythm Electrophysiol. 2022 Dec;15(12):e010915. doi: 10.1161/CIRCEP.122.010915. Epub 2022 Nov 28. PMID: 36441560; PMCID: PMC9760458. 12: Huynh K. RAPID return to sinus rhythm after SVT using intranasal etripamil. Nat Rev Cardiol. 2023 Sep;20(9):580. doi: 10.1038/s41569-023-00908-9. PMID: 37400625. 13: Stambler BS, Plat F, Sager PT, Lubkov V, Shardonofsky S, Wight D, Chen M, Camm AJ. Rationale for and design of a multicenter, placebo-controlled, phase 3 study to assess efficacy and safety of intranasal etripamil for the conversion of paroxysmal supraventricular tachycardia. Am Heart J. 2022 Nov;253:20-29. doi: 10.1016/j.ahj.2022.06.005. Epub 2022 Jun 18. PMID: 35728658. 14: Abuelazm M, Kambalapalli S, Saleh O, Elzeftawy MA, Albakri K, Gowaily I, Abdelazeem B. The Efficacy and Safety of Etripamil Nasal Spray for Acute Paroxysmal Supraventricular Tachycardia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Am J Cardiovasc Drugs. 2023 Jul;23(4):379-391. doi: 10.1007/s40256-023-00592-7. Epub 2023 Jun 23. PMID: 37351813; PMCID: PMC10328856. 15: Choe WC, Sundaram S, Boorman C, Mullins N, Shamszad P, Plat F. High-density mapping of the slow pathway in a patient with atrioventricular nodal reentry given intranasal Etripamil during the NODE-1 study. HeartRhythm Case Rep. 2017 Jul 27;3(10):479-482. doi: 10.1016/j.hrcr.2017.07.011. PMID: 29062702; PMCID: PMC5643855.